SPERM Stock Overview
Provides diagnostic health care products and services in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Spermosens AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.016 |
| 52 Week High | SEK 0.83 |
| 52 Week Low | SEK 0.01 |
| Beta | -0.24 |
| 11 Month Change | -27.27% |
| 3 Month Change | -45.21% |
| 1 Year Change | -97.01% |
| 33 Year Change | -99.88% |
| 5 Year Change | n/a |
| Change since IPO | -99.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| SPERM | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 23.1% | -5.8% | -2.1% |
| 1Y | -97.0% | 14.3% | 10.8% |
Return vs Industry: SPERM underperformed the Swedish Biotechs industry which returned 17.8% over the past year.
Return vs Market: SPERM underperformed the Swedish Market which returned 12.5% over the past year.
Price Volatility
| SPERM volatility | |
|---|---|
| SPERM Average Weekly Movement | 30.0% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: SPERM's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: SPERM's weekly volatility (30%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 3 | Tore Duvold | www.spermosens.com |
Spermosens AB provides diagnostic health care products and services in Sweden. The company offers male infertility fertility diagnostics and fertility treatments for the IVF market. It develops JUNO-Checked, a device that measures the binding between sperm and egg cell to enable individualized choice of fertility treatment based on measured binding.
Spermosens AB Fundamentals Summary
| SPERM fundamental statistics | |
|---|---|
| Market cap | SEK 3.29m |
| Earnings (TTM) | -SEK 9.74m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs SPERM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPERM income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 9.74m |
| Earnings | -SEK 9.74m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Nov 28, 2024
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2.8% |
How did SPERM perform over the long term?
See historical performance and comparison